Arbaclofen in Children and Adolescents with Autism Spectrum Disorder - podcast episode cover

Arbaclofen in Children and Adolescents with Autism Spectrum Disorder

May 12, 201710 min
--:--
--:--
Listen in podcast apps:
Metacast
Spotify
Youtube
RSS
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Autism Spectrum Disorder is a disorder that has been defined by the medical community, but so far, none of the medications available for ASD treat the core symptoms of the disease, but rather secondary symptoms such as agitation or hyperactivity. Because ASD is genetically linked to Fragile X syndrome, researchers noticed that in a mouse model, the drug arbaclofen reduced what would be core symptoms of autism, such as combatting social avoidance and improving social function. A randomized placebo-controlled trial was conducted to test this idea and the results were recently published in Neuropsychopharmacology. Listen to the latest BrainPod to hear Dr. Jeremy Veenstra-VanderWeele discuss these results!

Hosted on Acast. See acast.com/privacy for more information.

For the best experience, listen in Metacast app for iOS or Android
Open in Metacast
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder | NPP BrainPod podcast - Listen or read transcript on Metacast